Thalidomide treatment for hypertrophic cutaneous lupus erythematosus

Daniele Gambini, C. Carrera, E. Passoni, S. Muratori, E. Berti, R. Caputo

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: In recent years numerous reports have been published regarding satisfactory thalidomide therapy for refractory chronic cutaneous lesions of lupus erythematosus (CCLE); to date, in the literature, there is just one report describing two patients affected by hyperkeratotic CCLE successfully treated with thalidomide. METHODS: Six patients affected by a hypertrophic/verrucous variant of CCLE were treated with thalidomide during the period October 1999 to December 2002 and their medical records were retrospectively reviewed. The initial dose of thalidomide was 100mg/die by mouth for all the cases, while the duration of therapy was variable among the patients. RESULTS: All six patients responded to treatment: two had partial resolution of the lesions and four achieved almost complete clearing of cutaneous disease. Response to treatment was seen in the first month of therapy in all the patients. Follow-up nerve conduction studies were negative but a patient had to discontinue the drug because of neurological problems. DISCUSSION/CONCLUSION: Our case series confirms the efficacy of a 'low-dose' thalidomide regimen in verrucous/hyperkeratotic CCLE, which is normally unresponsive to conventional treatment; in this setting, thalidomide should be kept in mind as an extremely valid therapeutic option despite the lack of prospective, randomized, double-blind, placebo-controlled studies.

Original languageEnglish
Pages (from-to)365-371
Number of pages7
JournalJournal of Dermatological Treatment
Volume15
Issue number6
DOIs
Publication statusPublished - Dec 2004

Fingerprint

Cutaneous Lupus Erythematosus
Thalidomide
Discoid Lupus Erythematosus
Therapeutics
Neural Conduction
Skin Diseases
Medical Records
Mouth
Placebos

Keywords

  • Cutaneous lupus erythematosus
  • Thalidomide
  • Therapy

ASJC Scopus subject areas

  • Dermatology

Cite this

Thalidomide treatment for hypertrophic cutaneous lupus erythematosus. / Gambini, Daniele; Carrera, C.; Passoni, E.; Muratori, S.; Berti, E.; Caputo, R.

In: Journal of Dermatological Treatment, Vol. 15, No. 6, 12.2004, p. 365-371.

Research output: Contribution to journalArticle

@article{d64a4d0e95754d3eb8cedb149f38fb6f,
title = "Thalidomide treatment for hypertrophic cutaneous lupus erythematosus",
abstract = "INTRODUCTION: In recent years numerous reports have been published regarding satisfactory thalidomide therapy for refractory chronic cutaneous lesions of lupus erythematosus (CCLE); to date, in the literature, there is just one report describing two patients affected by hyperkeratotic CCLE successfully treated with thalidomide. METHODS: Six patients affected by a hypertrophic/verrucous variant of CCLE were treated with thalidomide during the period October 1999 to December 2002 and their medical records were retrospectively reviewed. The initial dose of thalidomide was 100mg/die by mouth for all the cases, while the duration of therapy was variable among the patients. RESULTS: All six patients responded to treatment: two had partial resolution of the lesions and four achieved almost complete clearing of cutaneous disease. Response to treatment was seen in the first month of therapy in all the patients. Follow-up nerve conduction studies were negative but a patient had to discontinue the drug because of neurological problems. DISCUSSION/CONCLUSION: Our case series confirms the efficacy of a 'low-dose' thalidomide regimen in verrucous/hyperkeratotic CCLE, which is normally unresponsive to conventional treatment; in this setting, thalidomide should be kept in mind as an extremely valid therapeutic option despite the lack of prospective, randomized, double-blind, placebo-controlled studies.",
keywords = "Cutaneous lupus erythematosus, Thalidomide, Therapy",
author = "Daniele Gambini and C. Carrera and E. Passoni and S. Muratori and E. Berti and R. Caputo",
year = "2004",
month = "12",
doi = "10.1080/09546630410018094",
language = "English",
volume = "15",
pages = "365--371",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Thalidomide treatment for hypertrophic cutaneous lupus erythematosus

AU - Gambini, Daniele

AU - Carrera, C.

AU - Passoni, E.

AU - Muratori, S.

AU - Berti, E.

AU - Caputo, R.

PY - 2004/12

Y1 - 2004/12

N2 - INTRODUCTION: In recent years numerous reports have been published regarding satisfactory thalidomide therapy for refractory chronic cutaneous lesions of lupus erythematosus (CCLE); to date, in the literature, there is just one report describing two patients affected by hyperkeratotic CCLE successfully treated with thalidomide. METHODS: Six patients affected by a hypertrophic/verrucous variant of CCLE were treated with thalidomide during the period October 1999 to December 2002 and their medical records were retrospectively reviewed. The initial dose of thalidomide was 100mg/die by mouth for all the cases, while the duration of therapy was variable among the patients. RESULTS: All six patients responded to treatment: two had partial resolution of the lesions and four achieved almost complete clearing of cutaneous disease. Response to treatment was seen in the first month of therapy in all the patients. Follow-up nerve conduction studies were negative but a patient had to discontinue the drug because of neurological problems. DISCUSSION/CONCLUSION: Our case series confirms the efficacy of a 'low-dose' thalidomide regimen in verrucous/hyperkeratotic CCLE, which is normally unresponsive to conventional treatment; in this setting, thalidomide should be kept in mind as an extremely valid therapeutic option despite the lack of prospective, randomized, double-blind, placebo-controlled studies.

AB - INTRODUCTION: In recent years numerous reports have been published regarding satisfactory thalidomide therapy for refractory chronic cutaneous lesions of lupus erythematosus (CCLE); to date, in the literature, there is just one report describing two patients affected by hyperkeratotic CCLE successfully treated with thalidomide. METHODS: Six patients affected by a hypertrophic/verrucous variant of CCLE were treated with thalidomide during the period October 1999 to December 2002 and their medical records were retrospectively reviewed. The initial dose of thalidomide was 100mg/die by mouth for all the cases, while the duration of therapy was variable among the patients. RESULTS: All six patients responded to treatment: two had partial resolution of the lesions and four achieved almost complete clearing of cutaneous disease. Response to treatment was seen in the first month of therapy in all the patients. Follow-up nerve conduction studies were negative but a patient had to discontinue the drug because of neurological problems. DISCUSSION/CONCLUSION: Our case series confirms the efficacy of a 'low-dose' thalidomide regimen in verrucous/hyperkeratotic CCLE, which is normally unresponsive to conventional treatment; in this setting, thalidomide should be kept in mind as an extremely valid therapeutic option despite the lack of prospective, randomized, double-blind, placebo-controlled studies.

KW - Cutaneous lupus erythematosus

KW - Thalidomide

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=10644244376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644244376&partnerID=8YFLogxK

U2 - 10.1080/09546630410018094

DO - 10.1080/09546630410018094

M3 - Article

C2 - 15764048

AN - SCOPUS:10644244376

VL - 15

SP - 365

EP - 371

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 6

ER -